Cortexyme (CRTX) Competitors $1.84 +0.07 (+3.95%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesTrends CRTX vs. CHRS, ADVM, SGMO, FMTX, OMCL, MDRX, HSTM, MOLN, GNFT, and SOPHShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Coherus BioSciences (CHRS), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Forma Therapeutics (FMTX), Omnicell (OMCL), Veradigm (MDRX), HealthStream (HSTM), Molecular Partners (MOLN), Genfit (GNFT), and SOPHiA GENETICS (SOPH). Cortexyme vs. Coherus BioSciences Adverum Biotechnologies Sangamo Therapeutics Forma Therapeutics Omnicell Veradigm HealthStream Molecular Partners Genfit SOPHiA GENETICS Cortexyme (NASDAQ:CRTX) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings. Is CRTX or CHRS more profitable? Cortexyme has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets CortexymeN/A -70.96% -63.53% Coherus BioSciences -0.15%N/A -24.44% Does the MarketBeat Community believe in CRTX or CHRS? Coherus BioSciences received 291 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 65.15% of users gave Coherus BioSciences an outperform vote while only 64.44% of users gave Cortexyme an outperform vote. CompanyUnderperformOutperformCortexymeOutperform Votes15464.44% Underperform Votes8535.56% Coherus BioSciencesOutperform Votes44565.15% Underperform Votes23834.85% Which has more volatility and risk, CRTX or CHRS? Cortexyme has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Do insiders and institutionals hold more shares of CRTX or CHRS? 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, CRTX or CHRS? Cortexyme has higher earnings, but lower revenue than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCortexymeN/AN/A-$89.94M-$2.97-0.62Coherus BioSciences$257.24M0.49-$237.89M-$0.08-13.75 Do analysts recommend CRTX or CHRS? Coherus BioSciences has a consensus price target of $6.13, indicating a potential upside of 456.82%. Given Coherus BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Coherus BioSciences is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media prefer CRTX or CHRS? In the previous week, Coherus BioSciences had 4 more articles in the media than Cortexyme. MarketBeat recorded 4 mentions for Coherus BioSciences and 0 mentions for Cortexyme. Coherus BioSciences' average media sentiment score of 0.32 beat Cortexyme's score of 0.00 indicating that Coherus BioSciences is being referred to more favorably in the news media. Company Overall Sentiment Cortexyme Neutral Coherus BioSciences Neutral SummaryCoherus BioSciences beats Cortexyme on 12 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.48M$2.93B$5.05B$8.82BDividend YieldN/A1.89%5.17%4.07%P/E Ratio-0.6245.44125.6917.78Price / SalesN/A359.341,179.7874.25Price / CashN/A160.0933.7732.53Price / Book0.463.734.684.68Net Income-$89.94M-$41.63M$119.54M$226.08M7 Day Performance9.52%-7.95%-2.46%-2.04%1 Month Performance131.45%-7.17%-4.08%0.06%1 Year Performance109.09%23.03%29.82%24.60% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.84+4.0%N/A+101.1%$55.48MN/A-0.6255CHRSCoherus BioSciences3.8225 of 5 stars$1.10+34.1%$6.13+456.8%-46.9%$94.65M$304.34M-13.75246High Trading VolumeADVMAdverum Biotechnologies4.1701 of 5 stars$6.17-1.3%$27.83+351.1%-32.5%$128.34M$3.60M-1.03190Analyst ForecastShort Interest ↓SGMOSangamo Therapeutics2.183 of 5 stars$1.95-0.5%$7.00+259.0%+369.9%$408.95M$176.23M0.00480Analyst RevisionGap UpFMTXForma TherapeuticsN/A$20.01flatN/A+0.0%$957.54M$100.56M-5.00166OMCLOmnicell3.4613 of 5 stars$41.82-1.4%$50.83+21.6%+26.7%$1.96B$1.15B0.003,650Analyst RevisionHigh Trading VolumeMDRXVeradigm1.2417 of 5 stars$10.51+0.7%$11.75+11.8%-15.9%$1.12B$1.50B0.008,000Gap UpHSTMHealthStream4.0314 of 5 stars$31.30-2.9%$31.50+0.6%+22.8%$980.58M$279.06M48.151,092MOLNMolecular Partners0.389 of 5 stars$5.20-4.8%$4.50-13.5%+19.8%$220.24M$7.84M0.00180GNFTGenfit1.4555 of 5 stars$4.31+1.2%$13.00+201.6%+27.1%$215.28M$41.31M0.00120SOPHSOPHiA GENETICS1.4237 of 5 stars$3.17-3.1%$6.50+105.0%-14.6%$213.78M$62.37M0.00520 Related Companies and Tools Related Companies Coherus BioSciences Alternatives Adverum Biotechnologies Alternatives Sangamo Therapeutics Alternatives Forma Therapeutics Alternatives Omnicell Alternatives Veradigm Alternatives HealthStream Alternatives Molecular Partners Alternatives Genfit Alternatives SOPHiA GENETICS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
